Contemp Clin Trials. 2022 Apr 16:106761. doi: 10.1016/j.cct.2022.106761. Online ahead of print.
ABSTRACT
BACKGROUND: The MEL-SELF trial is a randomised controlled trial of patient-led surveillance compared to clinician-led surveillance in people treated for localised cutaneous melanoma (stage 0, I, II). The primary trial aim is to determine if patient led-surveillance compared to clinician-led surveillance increases the proportion of participants who are diagnosed with a new primary or recurrent melanoma at a fast-tracked unscheduled clinic visit. The secondary outcomes include time to diagnosis of any skin cancer, psychosocial outcomes, acceptability, and resource use.
OBJECTIVE: The objective of this report is to outline and publish the pre-determined statistical analysis plan before the database lock and the start of analysis.
METHODS/DESIGN: The statistical analysis plan describes the overall analysis principles, including how participants will be included in each analysis, the presentation of the results, adjustments for covariates, the primary and secondary outcomes, and their respective analyses. In addition, we present the planned sensitivity and subgroup analyses. A separate analysis plan will be published for health economic outcomes.
RESULTS: The MEL-SELF statistical analysis plan has been designed to minimize bias in estimating effects of the intervention on primary and secondary outcomes. By pre-specifying analyses, we ensure the study’s integrity and believability while enabling the reproducibility of the final analysis.
CONCLUSION: This detailed statistical analysis plan will help to ensure transparency of reporting of results from the MEL-SELF trial.
TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12621000176864. Registered 18 February 2021, https://www.anzctr.org.au/ACTRN12621000176864.aspx.
PMID:35439647 | DOI:10.1016/j.cct.2022.106761
